´ëÇѳ»ºÐºñÇÐȸ SICEM 2022(The 10th Seoul International Congress of Endocrinology and Metabolism) (1ÀÏÂ÷) : 2022-10-28±³À°ÀÏÀÚ : 2022-10-28
±³À°Àå¼Ò : ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) SICEM 2022(The 10th Seoul International Congress of Endocrinology and Metabolism) (1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ¹Ú¼¼Çö
¿¬¶ôó : 02-2038-0072
À̸ÞÀÏ :
endo@endocrinology.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
±¤ÁÖ±¤¿ª½Ã±³À°½Ã°£ : 26 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 150,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-28 Room 1 08:30~09:20 Pre-Prediabetes: Time To Treat Ralph A. DEFRONZO(UT Health San Antonio)
ÈÞ½Ä 10-28 09:20~09:30 ÈÞ½Ä ()
±³À°½Ã°£ 10-28 Room 1 09:30~09:50 NAFLD and Cardiometabolic Diseases Marja-Riitta TASKINEN(University of Helsinki, Finland)
±³À°½Ã°£ 10-28 Room 1 09:50~10:10 New Insight of Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) ÀÓ¼ö(¼¿ïÀÇ´ë ºÐ´ç¼¿ï´ëº´¿ø ³»ºÐºñ´ë»ç³»°ú)
±³À°½Ã°£ 10-28 Room 1 10:10~10:30 Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease Ming-Hua ZHENG(Wenzhou Medical University, China)
Åä·Ð 10-28 Room 1 10:30~11:00 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 2 09:30~09:50 Key Players of Bone Metabolism ¹Ú¼®ÀÎ(°í·ÁÀÇ´ë »ýÈÇкÐÀÚ»ý¹°Çб³½Ç)
±³À°½Ã°£ 10-28 Room 2 09:50~10:10 Osteoclasts Recycle via Osteomorphs during RANKL-stimulated Bone Resorption Michelle M. MCDONALD(Garvan Institute of Medical Research)
±³À°½Ã°£ 10-28 Room 2 10:10~10:30 Bone Cell Plays in Energy Metabolism Megan M. WEIVODA(Division of Hematology, Mayo Clinic, USA)
Åä·Ð 10-28 Room 2 10:30~11:00 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 3 09:30~09:50 PFAS and Intersections with the Endocrine System Michele LA MERRILL(University of California, Davis)
±³À°½Ã°£ 10-28 Room 3 09:50~10:10 PFAS and Thyroid Function ±è¹ÎÁÖ(¼¿ïÀÇ´ë ¼¿ï´ëÇб³º´¿ø °³²¼¾ÅÍ)
±³À°½Ã°£ 10-28 Room 3 10:10~10:30 PFAS and Metabolism Bruce BLUMBERG(University of California, Irvine)
Åä·Ð 10-28 Room 3 10:30~11:00 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 4 09:30~09:50 The Latest Guideline Update for Complication Management ±è´ëÁß(¾ÆÁÖÀÇ´ë ¾ÆÁÖ´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú)
±³À°½Ã°£ 10-28 Room 4 09:50~10:10 How to Find the Optimal Combination for Initial T2DM Treatment? °½Å¾Ö(¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 10-28 Room 4 10:10~10:30 What is the Benefit of SGLT2+DPP4I Combination? ÀÌÁöÀº(À»ÁöÀÇ´ë ÀÇÁ¤ºÎÀ»Áö´ëº´¿ø ³»ºÐºñ³»°ú)
Åä·Ð 10-28 Room 4 10:30~11:00 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 5 09:30~09:50 Recent Updates on the Management of Thyroid Nodules ±è¹ÌÁø(ºÎ»êÀÇ´ë ºÎ»ê´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú)
±³À°½Ã°£ 10-28 Room 5 09:50~10:10 Recent Updates on the Management of Graves¡¯ Disease ÀÓµ¿ÁØ(°¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 10-28 Room 5 10:10~10:30 Recent Updates on the Management of Subclinical Hypothyroidism ±èÁøÈ(Á¶¼±ÀÇ´ë Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú)
Åä·Ð 10-28 Room 5 10:30~11:00 Åä·Ð ()
ÈÞ½Ä 10-28 11:00~11:10 ÈÞ½Ä ()
±³À°½Ã°£ 10-28 Room 1 11:30~12:10 SF-1 Targets in the Hypothalamus: A Molecular Link Between Energy Balance and Exercise Joel ELMQUIST(University of Texas)
±³À°½Ã°£ 10-28 Room 1 12:10~12:30 Key Updates on the Recent Guidelines - PCSK9 Inhibitors for Whom and When? (Endocrinology perspective) È«ÁØÈ(À»ÁöÀÇ´ë ´ëÀüÀ»Áö´ëº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 10-28 Room 1 12:30~12:50 How to Integrate Semaglutide into Clinical Practice - Focusing on case sharing in UK Adie VILJOEN(East and North Hertfordshire NHS Trust, UK)
±³À°½Ã°£ 10-28 Room 2 12:10~12:30 How to Find the Optimal Combination Therapy for Patients with Type 2 Diabetes ÇѽÂÁø(¾ÆÁÖÀÇ´ë ¾ÆÁִ뺴¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 10-28 Room 2 12:30~12:50 How to treat Hypertension in the Metabolic Syndrome Á¤¼öÁø(ºÎõ¼¼Á¾º´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 10-28 Room 3 12:10~12:30 Evogliptin CVOS: A Nationwide Cohort Study ¹ÚÁ¤È¯(ÇѾçÀÇ´ë ÇѾç´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú)
±³À°½Ã°£ 10-28 Room 3 12:30~12:50 Individualized T2DM Treatment: Focused on Recent Treatment Option ±è»ó¿ë(Á¶¼±ÀÇ´ë Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú)
½Ä»ç 10-28 12:50~13:10 ½Ä»ç ()
±³À°½Ã°£ 10-28 Room 1 14:00~14:40 Adrenal Pathology Update in 2022: What Clinical Endocrinologists Should Know Hironobu SASANO(Tohoku University)
ÈÞ½Ä 10-28 14:40~14:50 ÈÞ½Ä ()
±³À°½Ã°£ 10-28 Room 1 14:50~15:10 Roles of Denosumab in Cancer Treatment-induced Bone Loss È«¾Æ¶÷(Chonnam National University)
±³À°½Ã°£ 10-28 Room 1 15:10~15:30 Overcoming Difficulties of Osteoporosis Management in Patients with Kidney Disease David KENDLER(University of British Columbia, Canada)
±³À°½Ã°£ 10-28 Room 1 15:30~15:50 Managing Osteoporosis in Diabetes: Challenges and Strategies with RANKL Inhibitor Serge FERRARI(University of Geneva)
Åä·Ð 10-28 Room 1 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 2 14:50~15:10 The Genotype-Based Morphology of Aldosterone-producing Adrenocortical Disorders Hironobu SASANO(Tohoku University)
±³À°½Ã°£ 10-28 Room 2 15:10~15:30 Chemogenetic Activation of Adrenal Gq Signaling using DREADD technology Causes Hyperaldosteronism, Hypertension and Disrupts Functional Adrenal Zonation William RAINEY(University of Michigan)
±³À°½Ã°£ 10-28 Room 2 15:30~15:50 Primary Aldosteronism: What Do We Need to Monitor after Treatment Initiation? ±è°æÁø(Korea University)
Åä·Ð 10-28 Room 2 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 3 14:50~15:10 Endocrine Disruptors and Thyroid Dysfunction in Association with Autism Spectrum Disorder ½ÅÇü¹«(Baylor University)
±³À°½Ã°£ 10-28 Room 3 15:10~15:30 Iodine Nutrition and Thyroid Function in Korea ¼ÛÀ±ÁÖ(Food Science and Nutrition, The Catholic University of Korea)
±³À°½Ã°£ 10-28 Room 3 15:30~15:50 Potassium Iodide Therapy in Graves Nami SUZUKI(Ito hospital, Japan)
Åä·Ð 10-28 Room 3 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 4 14:50~15:10 Organoid Systems for Stem cells and Diseases Á¤¿µÅÂ(Department of New Biology, DGIST, Korea)
±³À°½Ã°£ 10-28 Room 4 15:10~15:30 Fusion of Regionally Specified hPSC-derived Organoids Models ¹ÚÀÎÇö(Yale University)
±³À°½Ã°£ 10-28 Room 4 15:30~15:50 Patient-derived Organoids Endometrial Disease Hugo VANKELECOM(KU Leuven)
Åä·Ð 10-28 Room 4 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 5 14:50~15:10 Recent Advances in NAFLD: A Diabetologist Perspective Paul Chi Ho LEE(The University of Hong Kong, Hong Kong SAR)
±³À°½Ã°£ 10-28 Room 5 15:10~15:30 Update on NAFLD as a Metabolic Disease Christos MANTZOROS(Harvard Medical School, USA)
±³À°½Ã°£ 10-28 Room 5 15:30~15:45 Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) ¹Ú¿µÁÖ(Seoul National University, Korea)
±³À°½Ã°£ 10-28 Room 5 15:45~16:00 Adrenal Diseases a Metabolic Perspective ±èÁ¤Èñ(Seoul National University, Korea)
Åä·Ð 10-28 Room 5 16:00~16:20 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 1 16:20~16:50 Thiazolidinediones and SGLT2i: A Rational Combination Based on T2DM Pathophysiology DeFronzo(UT Health San Antonio)
±³À°½Ã°£ 10-28 Room 1 16:50~17:20 The Role of Thiazolidinedione in Korean Type 2 Diabetes and Long-term Safety and Efficacy of Lobeglitazone ±è¼º·¡(The Catholic University of Korea)
Åä·Ð 10-28 Room 1 17:20~17:50 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 2 16:40~17:00 Iodine Intake and Thyroid Disease during and after Pregnancy in Korean Women ¾ÈÈ¿µ(Chung-Ang University)
±³À°½Ã°£ 10-28 Room 2 17:00~17:20 (Tentative Topic) Management of Thyroid Dysfunction in Pregnancy Kristien BOELAERT(University of Birmingham)
Åä·Ð 10-28 Room 2 17:20~17:50 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 3 16:20~16:40 Aging-related White Adipose Tissue Remodeling Qiong Annabel WANG(Molecular and Cellular Endocrinology, City of Hope, Comprehensive Cancer Center)
±³À°½Ã°£ 10-28 Room 3 16:40~17:00 HIF1a Signaling Drives Adipose Progenitor Dysfunction and Unhealthy Adipose Tissue Remodeling Mengle SHAO(Institut Pasteur of Shanghai, Chinese Academy of Sciences)
±³À°½Ã°£ 10-28 Room 3 17:00~17:20 Impacts of Extracellular Matrix Remodeling in Adipose Tissues in Obesity and Cancer ¹ÚÁö¿µ(Biological Sciences, School of Life Sciences, UNIST)
Åä·Ð 10-28 Room 3 17:20~17:50 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 4 16:20~16:40 The Emerging Role of Twincretin in the Management of Obesity ¼ÕÀå¿ø(The Catholic University of Korea, Korea)
±³À°½Ã°£ 10-28 Room 4 16:40~17:00 Obesity Treatment in Japan Koutaro Yokote(Chiba University Graduate School of Medicine, Japan)
±³À°½Ã°£ 10-28 Room 4 17:00~17:20 Novel Obesity Treatment: Matthias Blüher(University of Leipzig, Germany)
Åä·Ð 10-28 Room 4 17:20~17:50 Åä·Ð ()
±³À°½Ã°£ 10-28 Room 5 16:20~16:40 L-type Amino Acid Transporter 1 and Other Novel Treatment Options for Acromegaly Toru TATENO(University of Alberta)
±³À°½Ã°£ 10-28 Room 5 16:40~17:00 Treatment of Acromegaly by Rosiglitazone via Upregulating 15-PGDH in Both Pituitary Adenoma and Liver Zhaoyun ZHANG(Shanghai Medical College, Fudan University)
±³À°½Ã°£ 10-28 Room 5 17:00~17:20 Novel Therapeutic Target for Aggressive Cushing Hidenori FUKUOKA(Kobe University)
Åä·Ð 10-28 Room 5 17:20~17:50 Åä·Ð ()